Paloma Pharmaceuticals
Paloma Pharmaceuticals is an early-stage drug development company founded in 2005 in Jamaica Plain, Massachusetts, focused on pathologies involving aberrant up-regulation of biological targets. The firm has 1-10 employees, no disclosed products or pipeline, and minimal recent operational signals.
- Company typePrivate
- Founded2005
- HeadquartersJamaica Plain, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Paloma Pharmaceuticals firmographics
Firmographics- Name
- Paloma Pharmaceuticals
- Website
- https://palomapharma.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Paloma Pharmaceuticals is an early-stage drug development company founded in 2005 in Jamaica Plain, Massachusetts, focused on pathologies involving aberrant up-regulation of biological targets. The firm has 1-10 employees, no disclosed products or pipeline, and minimal recent operational signals.
- Ownership category
- akta.pro rank
Where Paloma Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Jamaica Plain
- HQ country
- United States
- HQ region
- North America
Markets served
Paloma Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Paloma Pharmaceuticals product offering
Product offeringCore offering
Paloma Pharmaceuticals, Inc. is an early-stage drug development company that focuses on pathologies showing an aberrant up-regulation of specific biological targets. The company engages in research activities aimed at developing therapeutic candidates for these specialized disease areas, operating from Jamaica Plain, Massachusetts.
Differentiator
Problem solved
Functional benefit
Companies that use Paloma Pharmaceuticals
Customer profileIdeal customer profiles1 record
Paloma Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Paloma Pharmaceuticals partnerships and signals
Strategic signalRecent moves3 records
Paloma Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Cytokinetics: Late-clinical-stage specialty pharma focused on muscle biology and cardiac sarcomere activation. Comparable as a focused, mechanism-driven small molecule drug developer with a small employee footprint and pipeline oriented to dysregulated physiological pathways.
- Madrigal Pharmaceuticals: Clinical-stage biopharma targeting a defined pathway (THR-β) in liver and metabolic disease. Comparable as a small, mechanism-focused pharmaceutical developer with a single-program-led strategy.
- Corcept Therapeutics: Specialty pharmaceutical company focused on modulating a single mechanistic pathway (cortisol/glucocorticoid receptor) in diseases of aberrant receptor signaling. Comparable to Paloma's focus on a defined biological mechanism with a small headcount and targeted therapeutic approach.
- Puma Biotechnology: Small-cap oncology drug developer targeting dysregulated signaling pathways (HER family). Comparable business model to Paloma as a focused, single-mechanism drug development company pursuing regulated-pathway biology.
- Geron Corporation: Clinical-stage biopharmaceutical company developing therapies targeting telomerase and telomeres—aberrantly regulated in certain hematologic diseases. Directly comparable in being a small, mechanism-focused drug developer.
- TG Therapeutics: Specialty biopharmaceutical company targeting immune pathway dysregulation in B-cell malignancies. Comparable in size and strategic posture as a mechanism-driven drug developer in oncology/immunology.
Broad incumbents
- Ligand Pharmaceuticals: Specialty pharma with a portfolio of small-molecule programs addressing dysregulated biology across multiple therapeutic areas. Comparable as a focused small-molecule drug developer serving as a royalty/sharing partner model.
- Lexicon Pharmaceuticals: Biopharmaceutical company developing drugs through genome biology, targeting genes whose dysregulation causes disease. Directly analogous mechanistic orientation to Paloma's stated focus.
- Forma Therapeutics (now part of Novo Nordisk): Was a clinical-stage biopharma focused on dysregulated cell biology in rare hematologic diseases and cancers. Comparable as a small-to-mid specialty drug developer that ultimately transacted with a major pharma acquirer.
Regional players
- CASI Pharmaceuticals: Biopharmaceutical company focused on developing and commercializing innovative therapeutics with high unmet need, particularly in hematology/oncology. Comparable as a smaller specialty pharma with pathway-targeted oncology assets.
Market position
Strengths3 records
Weaknesses4 records
Key risks5 records
Key highlights3 records
Customer concentration
Paloma Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paloma Pharmaceuticals leadership team
Management profileNumber of profiles
Paloma Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paloma Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paloma Pharmaceuticals
What does Paloma Pharmaceuticals do?
Paloma Pharmaceuticals, Inc. is an early-stage drug development company that focuses on pathologies showing an aberrant up-regulation of specific biological targets. The company engages in research activities aimed at developing therapeutic candidates for these specialized disease areas, operating from Jamaica Plain, Massachusetts.
Is Paloma Pharmaceuticals a public or private company?
Paloma Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was Paloma Pharmaceuticals founded?
Paloma Pharmaceuticals was founded in 2005. It employs 1 to 10 people.
Where is Paloma Pharmaceuticals based?
Paloma Pharmaceuticals is headquartered in Jamaica Plain, United States, in the North America region.
Who are Paloma Pharmaceuticals's main competitors?
Direct peers on record are Cytokinetics, Madrigal Pharmaceuticals, Corcept Therapeutics, Puma Biotechnology, Geron Corporation and TG Therapeutics. Broad incumbents are Ligand Pharmaceuticals, Lexicon Pharmaceuticals and Forma Therapeutics (now part of Novo Nordisk). CASI Pharmaceuticals is listed as a regional player.
Does Paloma Pharmaceuticals have an API?
No public API is recorded for Paloma Pharmaceuticals.